Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - HK
$ 6.13
0.822 %
$ 79.8 M
Market Cap
-19.16
P/E
CASH FLOW STATEMENT
-4 M
OPERATING CASH FLOW
5.24 M
INVESTING CASH FLOW
102 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Regencell Bioscience Holdings Limited
| Net Income | -4.36 M |
| Depreciation & Amortization | 746 K |
| Capital Expenditures | -5.38 K |
| Stock-Based Compensation | 449 K |
| Change in Working Capital | -585 K |
| Others | -833 K |
| Free Cash Flow | -4.01 M |
Cash Flow
Millions
| Jun-2024 | Jun-2023 | Jun-2022 | Jun-2021 | Jun-2020 | Jun-2019 | Dec-2017 | Dec-2016 | Dec-2015 | Jan-2015 | Dec-2013 | Dec-2012 | Dec-2010 | Dec-2009 | Jan-2009 | Dec-2007 | Dec-2006 | Dec-2004 | Jan-2004 | Dec-2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||||||
| Net Income | (4.4) | (6.1) | (7.6) | (1.3) | (0.8) | (0.4) | 112.3 | 170.4 | 153.4 | 105.6 | 157.7 | 144.8 | 77.6 | 95.5 | 72.0 | 363.0 | 86.0 | 82.0 | 185.0 | 117.0 |
| Depreciation & Amortization | 0.7 | 0.8 | 0.6 | 26.5 K | 9.52 K | 0 | 254.8 | 230.7 | 216.8 | 212.0 | 204.5 | 186.2 | 226.2 | 201.9 | 202.0 | 183.0 | 197.0 | 174.0 | 158.0 | 134.0 |
| Deferred Income Tax | 0 | 1.42 K | 0 | 0 | 0 | 0 | 0.6 | 2.4 | (10.9) | (6.6) | 11.8 | (52.4) | 7.5 | (1.1) | (18.0) | (4.0) | (19.0) | 2.0 | 26.0 | 73.0 |
| Stock Based Compensation | 0.4 | 0.9 | 2.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Operating Activities | (0.2) | 85.4 K | 10.7 K | 52.9 K | 19 K | 0 | 68.0 | 65.6 | 31.3 | 71.6 | (34.9) | 128.5 | (9.3) | 64.5 | 101.1 | (18.8) | 61.6 | 73.9 | 0 | 23.0 |
| Change in Working Capital | (0.6) | (0.5) | (1.0) | 0.6 | 76.3 K | 0 | (35.0) | (67.4) | 35.5 | (42.9) | (1.5) | (70.8) | (51.0) | 44.1 | (92.1) | 271.8 | (29.6) | 50.1 | 102.0 | 24.0 |
| Cash From Operations | (4.0) | (5.0) | (5.3) | (0.8) | (0.7) | (0.4) | 409.9 | 410.5 | 434.4 | 349.1 | 346.9 | 346.6 | 259.4 | 410.8 | 270.0 | 800.0 | 304.0 | 387.0 | 476.0 | 373.0 |
| INVESTING CASH FLOW | ||||||||||||||||||||
| Capital Expenditures | 5.38 K | 27.4 K | (0.8) | 0 | (0.1) | 0 | (250.4) | (214.9) | (185.7) | (156.8) | (112.1) | (89.2) | (98.4) | (108.8) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Items | 5.2 | 86.4 K | (10.0) | 0 | 0 | 0 | (160.2) | (8.7) | 2.4 | 287.2 | (37.1) | 158.8 | 15.7 | (1.7) | (338.0) | (47.0) | (151.0) | (306.0) | (181.0) | (115.0) |
| Cash From Investing Activities | 5.2 | 59 K | (10.8) | 0 | (0.1) | 0 | (410.6) | (223.6) | (183.3) | 130.4 | (149.2) | 69.6 | (82.7) | (110.5) | (338.0) | (47.0) | (151.0) | (306.0) | (181.0) | (115.0) |
| FINANCING CASH FLOW | ||||||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | (228.8) | 0 | 0 | (147.1) | (280.9) | (109.5) | (205.3) | (0.4) | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0.6 | 1.0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.1 | 0.1 | (0.3) | (0.2) | 0 | 0 | (17.0) | (160.0) | (178.6) | (332.4) | 83.2 | (306.7) | (299.5) | (142.4) | 0 | (480.0) | (186.0) | 0 | (281.0) | (50.0) |
| Cash From Financing Activities | 0.1 | 0.1 | 22.4 | 0.4 | 1.0 | 0.5 | (17.0) | (160.0) | (178.6) | (332.4) | 83.2 | (306.7) | (299.5) | (142.4) | 0 | (480.0) | (186.0) | 0 | (281.0) | (50.0) |
| CHANGE IN CASH | ||||||||||||||||||||
| Net Change In Cash | 1.4 | (4.9) | 6.4 | (0.3) | 0.1 | 90 K | (17.7) | 26.9 | 72.5 | (132.9) | 171.9 | (143.5) | (122.8) | 157.9 | (68.0) | 273.0 | (34.0) | 81.0 | 12.0 | 208.0 |
| FREE CASH FLOW | ||||||||||||||||||||
| Free Cash Flow | (4.0) | (5.0) | (6.0) | (0.8) | (0.8) | (0.4) | 159.5 | 195.6 | 248.7 | 192.3 | 234.8 | 257.4 | 161.0 | 302.0 | 270.0 | 800.0 | 304.0 | 387.0 | 476.0 | 373.0 |